Compare Neurocrine Biosciences Inc (NBIX) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Schwab US Large Cap Growth ETF — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Schwab US Large Cap Growth ETF trades at $34.24. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Schwab US Large Cap Growth ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | SCHG | |
|---|---|---|
Market Cap | $17.40B | — |
Sector | Health | Sector/Thematic |
52-Week High | $180.55 | $35.30 |
52-Week Low | $123.10 | $28.10 |
Enterprise Value | $16.49B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
